Current Price and Recent Performance
As of 17 Aug 2026, Epigral Ltd closed at ₹1,096.30, down 1.89% from the previous close of ₹1,117.40. The stock traded within a range of ₹1,092.30 to ₹1,121.35 during the day, remaining well below its 52-week high of ₹1,944.75, while comfortably above its 52-week low of ₹806.20. This price action underscores a persistent volatility and a struggle to regain previous highs.
Technical Trend and Indicator Analysis
Technical assessments reveal a deterioration in trend strength. The overall technical trend has shifted from mildly bearish to bearish, signalling increased downside risk. The daily moving averages reinforce this bearish stance, with the stock price trading below key averages, indicating downward momentum in the short term.
The Moving Average Convergence Divergence (MACD) presents a mixed picture. On a weekly basis, the MACD remains mildly bullish, suggesting some underlying positive momentum in the medium term. However, the monthly MACD is bearish, reflecting longer-term weakness and a lack of sustained buying interest.
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral zones without indicating overbought or oversold conditions. This lack of directional RSI momentum suggests indecision among traders and investors, complicating the outlook.
Bollinger Bands further confirm the bearish bias. Weekly Bollinger Bands are signalling bearish conditions, with the price gravitating towards the lower band, indicating selling pressure. Monthly Bollinger Bands are mildly bearish, reinforcing the cautious sentiment over a longer horizon.
The Know Sure Thing (KST) indicator aligns with this view, showing mildly bearish momentum on the weekly scale and bearish momentum monthly. This suggests that the stock’s price momentum is weakening across multiple timeframes.
Volume-based indicators such as On-Balance Volume (OBV) also point to mild bearishness on a weekly basis, indicating that volume trends are not supporting price advances. Monthly OBV remains neutral, suggesting no significant accumulation or distribution over the longer term.
Dow Theory analysis finds no definitive trend on either weekly or monthly charts, highlighting the absence of a clear directional market consensus for Epigral Ltd at present.
Comparative Returns and Market Context
When compared with the broader Sensex index, Epigral’s returns reveal a mixed performance. Over the past week, the stock declined by 0.49%, slightly outperforming the Sensex’s 0.62% fall. Over one month, Epigral gained 4.58%, significantly ahead of the Sensex’s 1.24% rise, indicating some short-term resilience.
However, year-to-date (YTD) returns show a decline of 10.09%, underperforming the Sensex’s 8.46% loss. The one-year return is particularly concerning, with Epigral down 41.52% compared to the Sensex’s modest 3.21% decline. This stark underperformance highlights sector-specific or company-specific challenges weighing on investor sentiment.
Longer-term returns over three years show a positive 22.02% gain, slightly outperforming the Sensex’s 19.28%, suggesting that despite recent setbacks, the company has delivered value over a multi-year horizon. Data for five and ten-year returns are not available for Epigral, but the Sensex’s robust 40.72% and 177.10% gains respectively set a high benchmark for comparison.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
Mojo Score and Ratings Update
Epigral Ltd’s MarketsMOJO score currently stands at 37.0, reflecting a Sell rating. This represents an upgrade from a previous Strong Sell grade assigned on 26 Dec 2025, indicating a slight improvement in outlook but still signalling caution for investors. The small-cap market capitalisation further emphasises the stock’s higher risk profile and potential volatility.
Technical Momentum and Moving Averages
The daily moving averages remain firmly bearish, with the stock price trading below its short-term and medium-term averages. This suggests that any rallies may face resistance and that the prevailing trend is downward. The weekly MACD’s mildly bullish stance offers some hope for a medium-term recovery, but the monthly MACD’s bearish signal tempers optimism.
The absence of clear RSI signals on weekly and monthly charts indicates that the stock is neither oversold nor overbought, which may result in a period of consolidation or sideways movement before a decisive trend emerges.
Volume and Trend Confirmation
Volume analysis via OBV shows mild bearishness on the weekly scale, implying that selling pressure is slightly outweighing buying interest. The lack of a monthly OBV trend suggests that longer-term investors are yet to commit decisively, which could lead to increased volatility as market participants await clearer signals.
Dow Theory’s lack of trend confirmation on both weekly and monthly timeframes further highlights the uncertainty surrounding Epigral’s price direction. This indecision may prompt cautious trading behaviour until a more definitive trend develops.
Epigral Ltd or something better? Our SwitchER feature analyzes this small-cap Specialty Chemicals stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Investor Takeaway and Outlook
Epigral Ltd’s technical indicators collectively suggest a cautious stance for investors. The shift from mildly bearish to bearish trends, combined with bearish moving averages and mixed MACD signals, points to potential downside risks in the near term. The lack of strong RSI or Dow Theory confirmation adds to the uncertainty, indicating that the stock may experience sideways or volatile trading before a clear trend emerges.
While the stock has shown some resilience over the past month with a 4.58% gain outperforming the Sensex, the significant underperformance over the past year (-41.52%) highlights structural challenges that investors should consider. The modest upgrade in Mojo Grade from Strong Sell to Sell reflects a slight improvement but still advises caution.
Given the small-cap nature of Epigral Ltd and its sector-specific risks within Specialty Chemicals, investors should weigh technical signals alongside fundamental factors before committing. Monitoring key support levels near ₹1,092 and resistance around ₹1,121 will be crucial in the coming sessions to gauge momentum shifts.
In summary, while there are pockets of mild bullishness on shorter timeframes, the prevailing technical landscape for Epigral Ltd remains bearish, suggesting that investors should remain vigilant and consider alternative opportunities within the sector or broader market.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
